30 tablets packing
Glimepiride is a second-generation sulfonylurea which can be used as mono therapy or in combination with other antihyperglycemic agents, including insulin.
Glimepiride is effective in reducing FPG, PPG, and HbA1c levels and is a useful, cost-effective treatment option for managing T2DM.
Although other SUs are used with insulin, glimepiride is the only SU approved by FDA for use in combination with insulin. It is used in more than 60 countries worldwide. Treatment with glimepiride as monotherapy results in a 1.5%–2.0% reduction in HbA1c
Supports physiological insulin regulation (more effective in reducing HbA1c, FPG, PPG),
Establishes fast and prolonged control of glycemia with reduced insulin secretion.
A better safety profile with less risk of hypoglycemia, as well as in patients with renal insufficiency
Not blocking desirable cardiovascular effects of ischemic preconditioning
Supports weight loss.
Enhances patients compliance
Preferable for concomitant use with all classes, including insulin
Additional useful extra pancreatic effects.
Reduces the number of abnormaly small LDL particles & tends to return decreased HDL levels to normal
Rapid as well as longer duration of action convenient for a once-a-day dosage - activity duration&dosage convenience
Possible effects of glimepiride beyond glycemic control in patients with type 2 diabetes:
Glimepiride may have potent anti-oxidative, anti-inflammatory and angiogenic properties and it may potentially repair tissue damage by decreasing the levels of toxic AGE and increasing colony-stimulating factors.